Company news

vTv Therapeutics Inc. news in 2023

vTv Therapeutics Inc.'s news releases, calls and decks from 2023, newest first.

View company

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

November 8, 2023

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

November 7, 2023

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

November 1, 2023

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

October 31, 2023

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

August 10, 2023

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

June 15, 2023

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 23, 2023

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 10, 2023

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 5, 2023

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

January 31, 2023

Decks in 2023